Impact Investing with Induran
Induran is a Venture Philanthropy General Partner
Impact Investing with Induran
Induran is a Venture Philanthropy General Partner
Where Venture Meets Philanthropy
Induran Venture Accomplishments
Induran accelerates ground breaking technologies that solve problems confronting humans. Induran has experience starting, growing, and running companies across the spectrum of biotechnology, including the world`s first continuous process bio fuel refinery, eco-friendly agriculture, anti viral therapeutics, drug delivery technology, novel therapeutics, and molecular diagnostics.
1 min clip from the Deal Flow Show
A short clip from the interview with CEO Peter Blaney on his investing philosophy. The full interview with The Deal Flow Show podcast covers how the pipeline stays full, what determines a good market and the effects of COVID-19 on the Biotech market.
Venture Philanthropy is Social Impact Investing
After productive careers in pharmaceuticals and venture capital the Induran Partners are focused on social impact investing, through venture philanthropy.
We have run philanthropic campaigns. And we have decades of experience investing in early stage companies developing life saving products.
We have worked with Family Offices, Qualified Investors, Angel Networks, and Multinational Corporations.
Invest in GraySpace for Social Impact
GraySpace Therapeutics Inc. is in the first wave of a new class of pharmaceutical companies that treat specific ailments by slowing fundamental processes associated with aging.
Our initial target is people suffering from neurodegenerative diseases like Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Ultimately our market will include approximately 2 billion adults over 40 years of age facing cognitive decline and neurodegenerative diseases.
Current Projects
SignPost Cancer Dx Inc.
Induran Ventures founded SignPost Cancer Dx Inc. to create BreastDefense and help advance the worlds shift to precision medicine.
SignPost is at the very forefront- globally- in the development of molecular diagnostics. If you would like to know more about SignPost visit: www.signpostcancerdx.com
GraySpace Therapeutics Inc.
At GraySpace Therapeutics we believe a successful key will be found in plasmalogens.
Few Pharma companies today have any experience or expertise with plasmalogens.
GraySpace is a world leader in plasmalogen research. Our scientists have been researching plasmalogens for several decades. GraySpace has a strong patent estate surrounding that research.
Past Projects
Performance Plants
A global leader in agricultural and biofuel biotechnology. A plant-trait company with field-tested proven technologies to help farmers, industry and biofuel users meet the challenges of feeding and fueling the world of tomorrow...today.
Defryus Inc.
Defyrus, developed an anti viral therapy ZMapp to treat Ebola. ZMapp was the first antibody therapy proven effective in treating humans, post exposure, for this highly infectious disease.
Biox
The world's first continuous process bio diesel refinery. Biox began as a test plant and now has two manufacturing locations in Canada and a joint venture with the US company World Energy of Houston.
Bio Diesel is a clean high performing alternative to petroleum diesel and is a low cost solution to help combat climate change.
Our Team
Peter Blaney
Barry Markowsky
Peter Blaney
For 30 years Peter has been active in biotechnology start ups that have led to products in bio fuels, agricultural biotech, anti viral therapeutics, drug delivery and molecular diagnostics.
Paul Lucas
Barry Markowsky
Peter Blaney
Paul is Past President and CEO of GlaxoSmithKline Canada. Paul has enormous experience in bringing new technology to the marketplace.
Barry Markowsky
Barry Markowsky
Barry Markowsky
Barry is Past Vice President Development and Director at GlaxoSmithKline Canada. Barry has the unique combination of a science background and experience in negotiating and closing development deals.